The Great Rotation: Russell 2000’s Historic 15-Day Streak Marks a Seismic Shift in Market Leadership In a move that has rewritten the record books of Wall Street, the small-cap-heavy Russell 2000 index recently concluded a historic 15-session winning streak of daily outperformance against the S&P 500. This rally, which reached its zenith on January 22, 2026, represents the longest period of small-cap dominance since
What Investors Should Know About a $1.5 Million Apogee Insider Sale Amid a 60% Stock Rally This clinical-stage biotech focused on long-acting antibody therapies reported a notable insider sale amid ongoing pipeline development.
Apogee Therapeutics Chief Medical Officer Sells $817,500 Worth of Shares After Monster December Rally This clinical-stage biotech focused on immunology therapies reported a notable insider sale amid ongoing pipeline development.
Why Apogee Therapeutics Stock Triumphed on Thursday The company aims to raise gross proceeds of roughly $300 million in a new capital-raising effort.
Why Apogee, A Rival To Regeneron And Sanofi, Rocketed 34% And Broke Out The small biotech company is looking to take on Regeneron and Sanofi's blockbuster, Dupixent.
What's going on in today's after hours session Discover the top movers in Wednesday's after-hours session and stay informed about the post-market dynamics.
Let's uncover which stocks are experiencing notable gaps during today's session. Today's session on Monday is marked by notable gaps in various stocks. Stay informed with the gap up and gap down stocks in today's session.
Apogee Reverses Lower Despite Promise For Twice-Yearly Eczema Shot Apogee Therapeutics shares crumbled Monday despite promising results for what could become a twice-yearly eczema shot.
What's going on in today's pre-market session Wondering what's happening in Monday's pre-market session? Find an overview in this article.
Apogee Therapeutics' Eczema Drug Provides Rapid Itch Relief In Phase 2 Trial Apogee's APG777 showed a 71% drop in eczema severity and strong itch relief in a Phase 2 trial for atopic dermatitis. Part B is ongoing.
Why Is Apogee Therapeutics Stock Trading Higher On Monday? Apogee's APG808 cut key asthma biomarker FeNO by 53% at 12 weeks with no severe adverse events, showing potential for long-term maintenance dosing.
Apogee Therapeutics' Investigational Atopic Dermatitis Potential Shows Strong Tolerability, Extended Half-Life in Early Trial Apogee's APG990 Phase 1 data show a 60-day half-life and strong tolerability, supporting long-interval dosing. A 2025 trial will compare APG279 to Dupixent.
